U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Physiology, NMDA Receptor

; .

Author Information and Affiliations

Last Update: December 11, 2022.

Introduction

The N-methyl-D-aspartate (NMDA) receptor is a receptor of glutamate, the primary excitatory neurotransmitter in the human brain. It plays an integral role in synaptic plasticity, which is a neuronal mechanism believed to be the basis of memory formation. NMDA receptors also appear to have involvement in a process called excitotoxicity. Excitotoxicity may play a role in the pathophysiology of a variety of diseases such as epilepsy or Alzheimer disease. Many drugs inhibit NMDA receptors, including ketamine and phencyclidine, two common drugs of abuse.

Cellular Level

Glutamate is the predominant excitatory neurotransmitter in the central nervous system. It binds to several different receptors, such as the AMPA, NMDA, and kainate receptors, each named after the laboratory molecule that selectively binds to them. These receptors often work in concert with one another in complex networks. The NMDA receptor is ionotropic and controls a ligand-gated ion channel. It is particularly important because it is integral in the processes of long-term potentiation, synaptic plasticity, and memory formation.[1]

There are multiple subtypes of NMDA receptors. Each receptor consists of two N1 subunits with either two N2 or two N3 subunits. The N1/N2 NMDA receptor complex is of primary physiological relevance. The receptor has several parts, including an extracellular ligand-binding domain and a transmembrane ion channel. When a ligand binds to the NMDA receptor, the ligand-binding domain closes like a clamshell. This closure leads to an opening of the transmembrane ion channel. The transmembrane ion channel is nonspecific for positively charged ions. However, due to the chemical properties of the channel and the concentrations of ions outside the cell, calcium ion often passes through the channel.[2] 

Regulation of the transmembrane ion channel is complex and multifactorial, allowing for precise control of ion permeability in physiologic conditions. Disruption of this regulation can be lethal to the cell. For the ion channel to open, several things must happen simultaneously. First, two molecules of either glycine or serine must bind to the NMDA receptor. Glycine will bind to extrasynaptic receptors; serine will bind to receptors located within the synapse. Second, two molecules of glutamate must bind to the receptor. However, the channel may not open even if it meets both of these. Magnesium and zinc both bind to sites on the NMDA receptor and block the transmembrane ion channel. This blockage prevents calcium ions from entering. For the channel to be permeable to calcium, magnesium or zinc must be dislodged from the cell by depolarization of the postsynaptic neuron. If another glutamate receptor, such as an AMPA receptor, is activated, it can depolarize the postsynaptic cell and dislodge magnesium or zinc, allowing the channel to open. In this way, the NMDA receptor serves as a coincidence detector. The channel will only open if the postsynaptic cell depolarizes at the same time that glutamate enters the synapse. Additionally, this allows a graded response to stimuli.[3] 

Three possible responses can occur, including short-term potentiation, long-term potentiation, and excitotoxicity. 

A small depolarization of the postsynaptic cells only partially dislodges magnesium or zinc, allowing a small number of calcium ions to enter the cell. These calcium ions serve as second messengers, which temporarily recruit more AMPA receptors to the cell. This recruitment allows for a higher chance of future depolarization. The effect of this change will only last for a few hours at most, so this process is known as short-term potentiation.

A large depolarization will completely dislodge magnesium or zinc, allowing a large volume of calcium to enter the cell. This calcium can interact with transcription factors, encouraging the growth of the neuron. This growth is known as long-term potentiation and is the mechanism behind synaptic plasticity. Synaptic plasticity is the brain's ability to "re-wire" itself. These effects can last for years.

An overwhelmingly prolonged depolarization will allow unregulated passage of calcium into the cell, which is lethal to it, and this effect is known as excitotoxicity. This process is known to occur in a multitude of neurological diseases.

Development

NMDA receptors are integral to the development of the brain. They help in the maturation of various glutamatergic synapses. Knockout studies of different NMDA receptor subunits have demonstrated neurologic deficits in animal models, such as failure to develop orientation selectivity in the visual cortex. NMDA receptors are involved in the regulation of synaptic plasticity and thus impact the lifelong development of the brain. Much research remains to elucidate the precise mechanisms of the NMDA receptor on brain development.[4]

Organ Systems Involved

The NMDA receptor has an integral role in synaptic plasticity and can delicately control ion permeability into the cell. Therefore, it is not surprising that it is virtually ubiquitous throughout the central nervous system. For example, roughly 80% of cortical neurons feature NMDA receptors. They preferentially express on pyramidal neurons. Curiously, they are also present on astrocytes, glial cells traditionally thought to support neurons.[5] NMDA receptors are also present within the hippocampus, where they appear to play a crucial role in memory formation.

NMDA receptors exist within the peripheral nervous system.[6] NMDA receptor subunits are also expressed in the kidney and cardiovascular system of the rat, though their purposes are unclear.[7]

Function

NMDA receptors are involved in myriad functions within the central nervous system.[6] Because this receptor allows a graded response to stimuli and precise control over calcium entry into the cell, it impacts many central nervous system functions. A classic example of NMDA receptor functionality is the acquisition of new memories. This memory encoding occurs via the process of long-term potentiation. The current belief is that the hippocampus is a critical brain area for this process.[8]

Pathophysiology

The NMDA receptor is involved in a variety of disease states, including: 

  • Alzheimer disease: NMDA receptors become severely disordered in this disease, a progressive and debilitating neurodegenerative disorder of unclear etiology. While the precise mechanisms of this remain unclear, it is well known that memantine, an NMDA receptor uncompetitive antagonist, improves Alzheimer symptoms.[9]
  • Huntington disease: This is a hereditary neurodegenerative disorder that also involves NMDA receptor-mediated excitotoxicity.[10] Memantine and amantadine, both NMDA receptor antagonists, reduce symptoms of Huntington disease.[11][12]
  • Epilepsy, stroke, and traumatic brain injury: These events involve calcium-mediated excitotoxicity. For example, in epilepsy, uncontrolled neuronal firing leads to excitotoxicity and permanent brain damage. It appears that similar processes occur in stroke and traumatic brain injury.[13]
  • Major depressive disorder: NMDA receptors may be involved in major depressive disorder, as ketamine, an NMDA receptor antagonist, has shown promise in its treatment.[14]
  • Tinnitus: NMDA receptors may be involved in the pathophysiology of tinnitus.[15]
  • Anti-NMDA receptor encephalitis: This is a rare, potentially lethal autoimmune encephalitis where autoantibodies are produced against the NMDA receptor. Patients present with psychiatric changes, epilepsy, motor, speech, or autonomic dysfunction, as well as decreased levels of consciousness. The diagnosis is by collecting anti-NMDA receptor antibodies from the patient's cerebrospinal fluid. This disease provides an excellent example of the ubiquity of NMDA receptors. When attacked by an autoimmune disease, dysfunction in numerous neurologic functions occurs. Treatment commonly involves steroids, intravenous immunoglobulin, and plasma exchange therapy. Anti-NMDA receptor encephalitis is often associated with ovarian teratomas.[16]
  • Heavy metal poisoning: Evidence suggests that in heavy metal poisoning, metals such as lead bind to NMDA receptors and may exert some of their toxic effects there.[17]
  • Migraines: Magnesium is a treatment for migraines, and NMDA receptors may be involved in their pathogenesis.[18][19]

Clinical Significance

Aside from their involvement in many disease pathophysiologies, NMDA receptors are the pharmacologic target of both therapeutic drugs and drugs of abuse. Several examples of these include: 

  • Ketamine: An NMDA antagonist, it is used as a sedative, anesthetic, off-label as an antidepressant, or recreationally as a hallucinogenic drug of abuse.[20]
  • Phencyclidine: An NMDA antagonist. It is used recreationally as a hallucinogenic, depersonalizing, euphoric drug of abuse. It reportedly causes homicidal and suicidal impulses in users. Users will characteristically experience nystagmus on physical exam.[21]
  • Ethanol: A common recreational drug, it modulates NMDA receptors through complex mechanisms.[22]
  • Memantine: An uncompetitive NMDA antagonist, this drug is used in the treatment of Alzheimer disease and off-label for Huntington disease.
  • Amantadine: An NMDA antagonist used in the treatment of Parkinson disease and off-label for Huntington disease.[23]
  • Magnesium: This naturally occurs in the transmembrane ion channel of the NMDA receptor. It is used to prevent migraines and abort migraine aura, prevent seizures in preeclampsia, and as a neuroprotective agent administered to mothers of premature infants to prevent neonatal brain damage.[24]
  • Methadone: A mu-opioid agonist and NMDA antagonist used in the treatment of opioid addiction.[25]

Review Questions

References

1.
Willard SS, Koochekpour S. Glutamate, glutamate receptors, and downstream signaling pathways. Int J Biol Sci. 2013;9(9):948-59. [PMC free article: PMC3805900] [PubMed: 24155668]
2.
Vyklicky V, Korinek M, Smejkalova T, Balik A, Krausova B, Kaniakova M, Lichnerova K, Cerny J, Krusek J, Dittert I, Horak M, Vyklicky L. Structure, function, and pharmacology of NMDA receptor channels. Physiol Res. 2014;63(Suppl 1):S191-203. [PubMed: 24564659]
3.
Kandel ER, Dudai Y, Mayford MR. The molecular and systems biology of memory. Cell. 2014 Mar 27;157(1):163-86. [PubMed: 24679534]
4.
Ewald RC, Cline HT. NMDA Receptors and Brain Development. In: Van Dongen AM, editor. Biology of the NMDA Receptor. CRC Press/Taylor & Francis; Boca Raton (FL): 2009. [PubMed: 21204419]
5.
Conti F. Localization of NMDA receptors in the cerebral cortex: a schematic overview. Braz J Med Biol Res. 1997 May;30(5):555-60. [PubMed: 9283622]
6.
McRoberts JA, Coutinho SV, Marvizón JC, Grady EF, Tognetto M, Sengupta JN, Ennes HS, Chaban VV, Amadesi S, Creminon C, Lanthorn T, Geppetti P, Bunnett NW, Mayer EA. Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats. Gastroenterology. 2001 Jun;120(7):1737-48. [PubMed: 11375955]
7.
Leung JC, Travis BR, Verlander JW, Sandhu SK, Yang SG, Zea AH, Weiner ID, Silverstein DM. Expression and developmental regulation of the NMDA receptor subunits in the kidney and cardiovascular system. Am J Physiol Regul Integr Comp Physiol. 2002 Oct;283(4):R964-71. [PubMed: 12228067]
8.
Rezvani AH. Involvement of the NMDA System in Learning and Memory. In: Levin ED, Buccafusco JJ, editors. Animal Models of Cognitive Impairment. CRC Press/Taylor & Francis; Boca Raton (FL): 2006. [PubMed: 21204373]
9.
Mota SI, Ferreira IL, Rego AC. Dysfunctional synapse in Alzheimer's disease - A focus on NMDA receptors. Neuropharmacology. 2014 Jan;76 Pt A:16-26. [PubMed: 23973316]
10.
Davies S, Ramsden DB. Huntington's disease. Mol Pathol. 2001 Dec;54(6):409-13. [PMC free article: PMC1187131] [PubMed: 11724916]
11.
Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord. 2007 Oct;13(7):453-4. [PubMed: 17046312]
12.
Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase TN. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002 Sep 10;59(5):694-9. [PubMed: 12221159]
13.
Zhou Q, Sheng M. NMDA receptors in nervous system diseases. Neuropharmacology. 2013 Nov;74:69-75. [PubMed: 23583930]
14.
Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-Sánchez E, Gutiérrez-Rojas L, Meana JJ. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review. CNS Drugs. 2018 May;32(5):411-420. [PubMed: 29736744]
15.
Noreña AJ. Revisiting the cochlear and central mechanisms of tinnitus and therapeutic approaches. Audiol Neurootol. 2015;20 Suppl 1:53-9. [PubMed: 25997584]
16.
Liu CY, Zhu J, Zheng XY, Ma C, Wang X. Anti-N-Methyl-D-aspartate Receptor Encephalitis: A Severe, Potentially Reversible Autoimmune Encephalitis. Mediators Inflamm. 2017;2017:6361479. [PMC free article: PMC5494059] [PubMed: 28698711]
17.
Karri V, Schuhmacher M, Kumar V. Heavy metals (Pb, Cd, As and MeHg) as risk factors for cognitive dysfunction: A general review of metal mixture mechanism in brain. Environ Toxicol Pharmacol. 2016 Dec;48:203-213. [PubMed: 27816841]
18.
Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain. 1994 Feb;117 ( Pt 1):199-210. [PubMed: 7908596]
19.
Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002 Jun;22(5):345-53. [PubMed: 12110110]
20.
Abdallah CG, Sanacora G, Duman RS, Krystal JH. The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? Pharmacol Ther. 2018 Oct;190:148-158. [PMC free article: PMC6165688] [PubMed: 29803629]
21.
Bertron JL, Seto M, Lindsley CW. DARK Classics in Chemical Neuroscience: Phencyclidine (PCP). ACS Chem Neurosci. 2018 Oct 17;9(10):2459-2474. [PubMed: 29953199]
22.
Kumari M, Ticku MK. Regulation of NMDA receptors by ethanol. Prog Drug Res. 2000;54:152-89. [PubMed: 10857388]
23.
Raupp-Barcaro IF, Vital MA, Galduróz JC, Andreatini R. Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials. Braz J Psychiatry. 2018 Oct-Dec;40(4):449-458. [PMC free article: PMC6899375] [PubMed: 29898194]
24.
Connolly E, Worthley LI. Intravenous magnesium. Crit Care Resusc. 1999 Jun;1(2):162-72. [PubMed: 16602999]
25.
Aiyer R, Mehta N, Gungor S, Gulati A. A Systematic Review of NMDA Receptor Antagonists for Treatment of Neuropathic Pain in Clinical Practice. Clin J Pain. 2018 May;34(5):450-467. [PubMed: 28877137]

Disclosure: Benjamin Jewett declares no relevant financial relationships with ineligible companies.

Disclosure: Bicky Thapa declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK519495PMID: 30137779

Views

  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...